Tumor cells often hijack normal physiological processes to support their growth, exploiting proteins that are in charge of essential cell functions.
Pfizer’s gene therapy for Duchenne muscular dystrophy fails in Phase 3 trial
Pfizer said Wednesday afternoon that a closely watched gene therapy for Duchenne muscular dystrophy failed to slow the disease’s progression in a Phase 3 trial.
June 12, 2024